Skip to main navigation Skip to search Skip to main content

Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy-let's define who benefits the most

Eric Santoni-Rugiu*, Jens Benn Sørensen, Edyta Maria Urbanska

*Corresponding author for this work
2 Citations (Scopus)
Original languageEnglish
JournalTranslational lung cancer research
Volume14
Issue number2
Pages (from-to)310-313
Number of pages4
ISSN2218-6751
DOIs
Publication statusPublished - 28 Feb 2025

Keywords

  • Adjuvant alectinib
  • anaplastic lymphoma kinaserearranged NSCLC (ALK-rearranged NSCLC)
  • resected early-stage non-small cell lung cancer (resected early-stage NSCLC)

Cite this